查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
精準醫學：主要趨勢、區域分析和市場預測 (2022-2027)
市場調查報告書
商品編碼
1152710

精準醫學：主要趨勢、區域分析和市場預測 (2022-2027)

Precision Medicine: Key Trends, Regional Analysis and Market Forecasts 2022-2027
出版日期: | 出版商: Juniper Research Ltd | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

到 2027 年，全球精準醫學支出預計將達到 1323 億美元，而 2022 年僅為 357 億美元。 270% 的強勁增長是人工智能等新技術和基礎設施的結果，它通過預測某些疾病的風險來協助精準醫療。這些技術進步，加上經濟低迷時期對醫療保健行業效率的需求，將鼓勵供應商對精準醫療進行更多投資。

在這份報告中，我們分析了全球精準醫療市場，提供了系統概覽、滲透狀態、整體市場規模趨勢展望（未來五年），以及按行業、地區和行業劃分的詳細趨勢行業、市場競爭格局、未來增長潛力與挑戰、主要企業概況（共15家企業）等。

主要市場統計數據

2022 年市場規模 357 億美元
2027 年市場規模 1323 億美元
支出增加（2022-2027 年） 270%

公司分析

  • Juniper Research 競爭對手排行榜公司：Abbott Laboratories、Almac Group、AstraZeneca、Asuragen、Biomerieux、Bristol-Myers Squibb、Cepheid、Ge HealthCare、IBM、Illumina、LabCorp、Novartis、Qiagen、Quest Diagnostics , 賽默飛世爾科技
  • 提及的公司：DNAnexus、Dragonfly、Genomics England、GNS Healthcare、GRAIL、Interscience、Janssen、Kaiku Health、Kura Oncology、LabShares、Loxo Oncology、Lyon Civil Hospitals、Merck、Millennium Pharmaceuticals、Mirrhia , Myriad Genetics, Obsidian Therapeutics, Ono, Paige（病理人工智能指導引擎）, Partners HealthCare, PathAI, Personal Genome Diagnostics, Pfizer, Qiagen, Roche, 上海兒童醫學中心, The Max Foundation, Turning Point Therapeutics, Walmart, Wave Life科學，惠康桑格研究所

內容

第 1 章分析概述和戰略建議

第二章市場展望

  • 精準醫學生態系統：概述
    • 精準醫學的趨勢
      • 傳統醫學
      • 分層醫學
  • 精準醫學技術
    • 人工智能和機器學習
    • 數據
    • 生物標誌物
    • 下一代測序
  • 治療
    • 免疫療法
    • CAR-T 細胞療法
    • 伴隨診斷
  • 精準醫療的優勢
    • 對消費者的好處
    • 對醫療公司的好處
  • 主要市場驅動因素分析
  • 約束因素

第三章區域分析

  • 按地區分析
    • 北美
      • 美國
      • 加拿大
    • 拉丁美洲
      • 墨西哥
      • 巴西
    • 西歐
      • 德國
      • 英國
    • 中歐和東歐
      • 克羅地亞
      • 土耳其
    • 遠東/中國
      • 中國
      • 韓國
    • 印度次大陸
      • 印度
      • 巴基斯坦
    • 亞太地區
      • 澳大利亞
      • 菲律賓
    • 非洲/中東
      • 埃及
      • 阿拉伯聯合酋長國 (UAE)

第 4 章競爭對手排行榜和供應商概況

  • 精密醫學：供應商簡介
    • Almac Group Ltd.
    • AstraZeneca
    • Asuragen
    • Biomerieux
    • Bristol-Myers Squibb
    • Cepheid Inc
    • GE HealthCare
    • IBM
    • Illumina
    • LabCorp
    • Novartis
    • Qiagen
    • Quest Diagnostics
    • Thermo Fisher Scientific

第五章市場預測

  • 簡介
    • 預測和調查方法
    • 為精準醫學進行的基因測試總數
    • 精準醫學基因檢測的總成本
    • 精準醫學治療的總支出
    • 精密醫學總收入
簡介目錄

REPORT OVERVIEW

Juniper Research's “Precision Medicine report” provides a detailed evaluation of the technological advancements in the field of precision medicine and demand for precision medicine, including the adoption of precision medicine within both developing markets and established markets. In addition, this report, focusing on precision medicine initiatives, covers market opportunities; providing strategic insights into the technologies and key drivers that are pushing the space forward, and the role of key market players; 15 leading precision medicine vendors across the market.

This extensive research suite covering advances in precision medicine also contains a detailed dataset; providing forecasts for 60 countries across a number of different metrics, including the number of patients being tested for precision medicine purposes, the number of genetic tests carried out for precision medicine, the total number of precision medicine patients receiving personalised treatment, the total spend on precision medicine testing and treatment and total precision medicine revenue.

This precision medicine market report research suite comprises of:

  • Strategy & Forecasts (PDF)
  • 5-year Market Sizing & Forecast Spreadsheet (Excel)
  • 12 Months Access to harvest Online Data Platform

Key Market Statistics

Market size in 2022:$35.7bn
Market size in 2027:$132.3bn
2022 to 2027 Spend Growth:270%

KEY FEATURES

  • Market Dynamics: This section of the precision medicine study features strategic analysis of the major drivers, challenges, and innovations shaping the adoption and development of precision medicine, with key factors including the following market segmentation:
    • COVID-19 pandemic impact on the precision medicine market
    • Future strategic direction, market share and market outlook for precision medicine
    • Key issues precision medicine vendors must be aware of surrounding legislation and data sharing
  • Regional Analysis: A regional market-level analysis of 16 countries, spanning 8 key regions within the healthcare infrastructure; covering the current deployment level of precision medicine applications and the future outlook of precision medicine in each market.
  • Key Takeaways & Strategic Recommendations: Analysis of a wide range of key development opportunities and major factors within the market for precision medicine in the healthcare industry, accompanied by key strategic recommendations for stakeholders.
  • Benchmark Industry Forecasts: Investigating lucrative growth of precision medicine market size in full; including forecasts for the total number of patients taking genetic tests for precision medicine, the total number of genetic tests carried out for precision medicine, total number of precision medicine patients receiving medical treatment options and precision medicine drugs, total spend on precision medicine test and treatment, and total precision medicine revenue. This precision medicine market growth data is split by our 8 key forecast regions and 60 countries:
    • North America:
      • Canada, United States
    • Latin America:
      • Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay
    • West Europe:
      • Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom
    • Central & East Europe:
      • Croatia, Czech Republic, Hungary, Poland, Romania, Russia, Turkey, Ukraine
    • Far East & China:
      • China, Hong Kong, Japan, South Korea
    • Indian Subcontinent:
      • Bangladesh, India, Nepal, Pakistan
    • Rest of Asia Pacific:
      • Australia, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam
    • Africa & Middle East:
      • Algeria, Egypt, Israel, Kenya, Kuwait, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates
  • Juniper Research Competitor Leaderboard: Key player capability and capacity assessment in the healthcare sector for 15 precision medicine vendors:
    • Abbott Laboratories
    • Almac Group Ltd
    • AstraZeneca
    • Asuragen Inc
    • Biomérieux Sa
    • Bristol-Myers Squibb
    • Cepheid Inc
    • Ge Healthcare
    • IBM
    • Illumina Inc
    • Laboratory Corporation of America Holdings
    • Novartis
    • Qiagen
    • Quest Diagnostics
    • Thermo Fisher Scientific Inc.

KEY QUESTIONS ANSWERED

  • 1. How will key market trends affect projected precision medicine adoption?
  • 2. What technologies will accelerate precision medicine?
  • 3. Who are the leading vendors in the precision medicine market?
  • 4. What limitations are there holding back precision medicine?
  • 5. In which regions will precision medicine be most successful?

COMPANIES REFERENCED

  • Included in the Juniper Research Competitor Leaderboard: Abbott Laboratories, Almac Group, AstraZeneca, Asuragen, Biomerieux, Bristol-Myers Squibb, Cepheid, Ge HealthCare, IBM, Illumina, LabCorp, Novartis, Qiagen, Quest Diagnostics, Thermo Fisher Scientific.
  • Mentioned: DNAnexus, Dragonfly, Genomics England, GNS Healthcare, GRAIL, Interscience, Janssen, Kaiku Health, Kura Oncology, LabShares, Loxo Oncology, Lyon Civil Hospitals, Merck, Millennium Pharmaceuticals, Mirrhia, Myriad Genetics, Obsidian Therapeutics, Ono, Paige (Pathology Artificial Intelligence Guidance Engine), Partners HealthCare, PathAI, Personal Genome Diagnostics, Pfizer, Qiagen, Roche, Shanghai Children's Medical Centre, The Max Foundation, Turning Point Therapeutics, Walmart, Wave Life Science, Wellcome Sanger Institute.

DATA & INTERACTIVE FORECAST

Key Market Forecast Splits

  • Diagnosis
  • Treatment

Metrics including the number of precision medicine patients, number of genetic tests carried out for precision medicine, total number of precision medicine patients receiving treatment, total spend on precision medicine test and treatment and total precision medicine revenue.

  • Geographical splits: 60 countries
  • Number of tables: Over 18 tables
  • Number of datapoints: Over 12,000 datapoints

harvest: Our online data platform, harvest, contains the very latest market data and is updated throughout the year. This is a fully featured platform enabling clients to better understand key data trends and manipulate charts and tables; overlaying different forecasts within the one chart - using the comparison tool. Empower your business with our market intelligence centre, and receive alerts whenever your data is updated.

Interactive Excels (Ifxl): Our Ifxl tool enables clients to manipulate both forecast data and charts, within an Excel environment, to test their own assumptions using the interactive scenario tool and compare selected markets side by side in customised charts and tables. Ifxls greatly increase a client's ability to both understand a particular market and to integrate their own views into the model.

FORECAST SUMMARY

The total spend on precision medicine will reach $132.3 billion globally by 2027; increasing from only $35.7 billion in 2022. This strong growth of 270% is a result of emerging technologies and infrastructure, such as AI, which aids precision medicine by predicting risks for certain diseases. These technological advancements, combined with the healthcare sector's need to increase efficiencies in the face of an economic downturn, will encourage healthcare providers to invest further into precision medicine.

  • Benefits such as reductions in adverse reactions from ineffective medication, improving the efficacy of treatments plans via personalisation, and cutting patient spend on medication, will be the primary drivers of precision medicine adoption amongst healthcare providers. To maximise these benefits, the report identified the use of AI to ingest and process large amounts of healthcare data to increase the future accuracy of diagnoses.
  • The most significant issue surrounding precision medicine will arise from patient data privacy concerns. In many countries, but predominantly the US, there are fears that the uncovering of genetic predispositions using precision medicine will lead to insurance providers leveraging these insights to increase healthcare premiums. To allay these concerns, vendors must consider voluntarily adopting strong codes of conduct around data privacy, as well as creating independent advisory councils, to reassure users and limit the scope of data sharing.

Table of Contents

1. Key Takeaways & Strategic Recommendations

  • 1.1. Key Takeaways & Strategic Recommendations
  • 1.2. Strategic Recommendations

2. Future Market Outlook

  • 2.1. Overview of the Precision Medicine Ecosystem
    • Figure 2.1: Diagram Displaying Process of Precision Medicine
    • 2.1.1. Development of Precision Medicine
      • i. Traditional Medicine
      • ii. Stratified Medicine
  • 2.2. Technology in Precision Medicine
    • Figure 2.2: Diagram Displaying Stakeholders Involved in Precision Medicine
    • 2.2.1. Artificial Intelligence and Machine Learning
    • 2.2.2. Data
    • 2.2.3. Biomarkers
    • 2.2.4. Next-generation Sequencing
  • 2.3. Treatment
    • 2.3.1. Immunotherapies
    • 2.3.2. CAR T Cell Therapies
    • 2.3.3. Companion Diagnostics
  • 2.4. Benefits of Precision Medicine
    • 2.4.1. Benefits for Consumers
      • i. Time Saving
      • ii. Prevention of Adverse Reactions
      • iii. Cost Saving
    • 2.4.2. Benefits for Healthcare Corporates
      • i. Shift from Reaction to Prevention
      • ii. Reduction in Trial-and-Error Prescribing
      • iii. Increase in the Healthcare Database
      • iv. Improve Patient Adherence to Treatment
  • 2.5. Exploration of Key Market Drivers
  • 2.6. Limitations

3. Regional Analysis

  • 3.1. Regional Analysis
    • 3.1.1. North America
      • i. US
      • ii. Canada
    • 3.1.2. Latin America
      • i. Mexico
      • ii. Brazil
    • 3.1.3. West Europe
      • i. Germany
      • ii. UK
    • 3.1.4. East & Central Europe
      • i. Croatia
      • ii. Turkey
    • 3.1.5. Far East & China
      • i. China
      • ii. South Korea
    • 3.1.6. Indian Subcontinent
      • i. India
      • ii. Pakistan
    • 3.1.7. Asia Pacific
      • i. Australia
      • ii. Philippines
    • 3.1.8. Africa & Middle East
      • i. Egypt
      • ii. United Arab Emirates

4. Competitor Leaderboard and Vendor Profiles

  • Table 4.1: Juniper Research Competitor Leaderboard: Precision Medicine Vendors Included & Product Portfolio
  • Figure 4.2: Juniper Research Leaderboard: Precision Medicine Vendors
  • Table 4.3: Juniper Research Leaderboard: Precision Medicine Vendors & Positioning
  • Table 4.4: Juniper Research Leaderboard Heatmap: Precision Medicine
  • 4.1. Precision Medicine - Vendor Profiles
    • 4.1.1. Abbott Laboratories
      • i. Corporate
        • Table 4.5: Abbott Laboratories' Financial Snapshot ($m), FY 2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.2. Almac Group Ltd.
      • i. Corporate
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.3. AstraZeneca
      • i. Corporate
        • Table 4.6: AstraZeneca's Financial Snapshot ($b), FY 2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.4. Asuragen
      • i. Corporate
      • ii. Geographical Spread
      • iii. Key Clients & Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.5. Biomerieux
      • i. Corporate
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.6. Bristol-Myers Squibb
      • i. Corporate
        • Table4.7: Bristol-Myers Squibb's Financial Snapshot ($b), FY 2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.7. Cepheid Inc
      • i. Corporate
      • ii. Geographical Spread
      • iii. Key Clients & Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.8. GE HealthCare
      • i. Corporate
        • Table 4.8: GE HealthCare's Financial Snapshot ($b), FY 2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients & Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.9. IBM
      • i. Corporate
        • Table 4.9: IBM's Financial Snapshot ($b), FY 2019-2021 (FYE 31st December)
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.10. Illumina
      • i. Corporate
        • Table 4.10: Illumina's Financial Snapshot ($b), FY 2021-2022
      • ii. Geographical Spread
      • iii. Key Clients & Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.11. LabCorp
      • i. Corporate
        • Table 4.11: LabCorp's Financial Snapshot ($b), FY 2020-2021
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.12. Novartis
      • i. Corporate
        • Table 4.12: Novartis' Financial Snapshot ($b), FY 2020-2021
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.13. Qiagen
      • i. Corporate
      • ii. Geographical Spread
      • iii. Key Clients & Partnerships
      • iv. High-level View of Offerings
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.14. Quest Diagnostics
      • i. Corporate
        • Table 4.13: Quest Diagnostics' Financial Snapshot ($b), FY 2020-2021
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level View of Offerings
        • Figure 4.14: Diagram Displaying Quest Diagnostics' Companion Diagnostics Development
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
    • 4.1.15. Thermo Fisher Scientific
      • i. Corporate
      • ii. Geographical Spread
      • iii. Key Clients and Partnerships
      • iv. High-level View of Offerings
        • Figure 4.15: Thermo Fishers Scientific Pharmacogenomics
      • v. Juniper Research's View: Key Strengths & Strategic Development Opportunities
        • Table 4.16: Juniper Research Competitor Leaderboard Scoring Criteria

5. Market Forecasts

  • 5.1. Introduction
    • 5.1.1. Precision Medicine Forecast Methodology
      • Figure 5.1: Precision Medicine Revenue Methodology
    • 5.1.2. Total Number of Precision Medicine Genetic Tests
      • Figure & Table 5.2: Total Precision Medicine Genetic Tests, Split by 8 Key Regions, 2022-2027
    • 5.1.3. Total Spend on Genetic Testing for Precision Medicine
      • Figure & Table 5.3: Total Spend on Genetic Testing for Precision Medicine ($m), Split by 8 Key Regions, 2022-2027
    • 5.1.4. Total Spend on Precision Medicine Treatment
      • Figure & Table 5.4: Total Spend on Precision Medicine Treatment ($m), Split by Key Regions, 2022-2027
    • 5.1.5. Total Precision Medicine Revenue
      • Figure 5.5: Total Precision Medicine Revenue ($m), Split by 8 Key Regions, 2022-2027